CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
English• In recent published literature, a low Body Mass Index (BMI) condition, defined as a value <18.5, is mostly evaluated in low/middle-income settings while in Western Countries it was frequently evaluated in the pre- or early antiretroviral treatment (ART) era. • Nevertheless, in recent years BMI and weight gain returned to be investigational issues especially for the observed excessive weight increase under integrase strand-transfer inhibitors (INSTI) treatment, especially with dolutegravir (DTG) and raltegravir (RAL) use. • A BMI <18.5 cumulatively affects about 5% of HIV-infected population and might be related not only to complex clinical conditions but also to socio-economic issues. • A BMI <18.5 is associated with an increased risk of death for both cardiovascular and neoplastic disease (with an OR 2.47 for males and 1.60 for females). • An excessive weight gain in the first year of treatment has a strong impact on the development of cardiovascular disease and diabetes. • However, a low BMI at baseline could have different meaning and diverse consequences compared to a persisting low BMI after ART start; additionally, few data are available on BMI normalization (expression of general conditions improvement) in terms of virologic and immunologic recovery, especially with the availability of modern ART drugs.
| Titolo: | Low Body Mas Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort. |
| Autori: | |
| Data di pubblicazione: | 2019 |
| Rivista: | |
| Abstract: | • In recent published literature, a low Body Mass Index (BMI) condition, defined as a value <18.5, is mostly evaluated in low/middle-income settings while in Western Countries it was frequently evaluated in the pre- or early antiretroviral treatment (ART) era. • Nevertheless, in recent years BMI and weight gain returned to be investigational issues especially for the observed excessive weight increase under integrase strand-transfer inhibitors (INSTI) treatment, especially with dolutegravir (DTG) and raltegravir (RAL) use. • A BMI <18.5 cumulatively affects about 5% of HIV-infected population and might be related not only to complex clinical conditions but also to socio-economic issues. • A BMI <18.5 is associated with an increased risk of death for both cardiovascular and neoplastic disease (with an OR 2.47 for males and 1.60 for females). • An excessive weight gain in the first year of treatment has a strong impact on the development of cardiovascular disease and diabetes. • However, a low BMI at baseline could have different meaning and diverse consequences compared to a persisting low BMI after ART start; additionally, few data are available on BMI normalization (expression of general conditions improvement) in terms of virologic and immunologic recovery, especially with the availability of modern ART drugs. |
| Handle: | http://hdl.handle.net/11570/3147224 |
| Appare nelle tipologie: | 14.d.1 Abstract in Atti di convegno |
File in questo prodotto:
Copyright © 2021